Central South Carolina Pharmacy, Independent Retail Pharmacy

$18.1M

Revenue

$778K

SDE

3.5x

Multiple

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

Central South Carolina Pharmacy is an independent retail pharmacy doing roughly $18.1M in annual revenue with $778K in EBITDA. The business is fully staffed with pharmacists and support personnel, and the listing explicitly markets it as absentee-operable, meaning the owner is not the primary pharmacist or day-to-day operator. For a buyer, that combination of scale and an existing team is attractive because it de-risks the transition and does not require the buyer to hold a pharmacist license personally.

The core business is dispensing prescription medications, which is about as non-discretionary as retail gets. Patients on maintenance medications for chronic conditions refill month after month, which creates a sticky, repeat-revenue base that is far more durable than typical retail foot traffic. The margin profile is thin on a percentage basis (EBITDA margin around 4.3% on $18M of revenue), which is characteristic of pharmacy economics where reimbursement rates and wholesale drug costs compress the spread.

At a $2.75M ask against $778K EBITDA, the deal prices at about 3.53x, which sits in a reasonable band for an independent pharmacy. The key question for any buyer is whether that revenue and margin are reimbursement-stable, because pharmacy profitability lives and dies on payer mix, PBM contracts, and DIR fee dynamics that can swing earnings without any change in prescription volume.

Why we like it

Earnings quality is anchored in recurring prescription refills rather than one-off sales, because patients on chronic maintenance drugs return every 30 to 90 days by default. That gives the $18.1M revenue base a predictable floor that is largely insulated from consumer sentiment. The $778K EBITDA is real cash flow from an essential service, not seasonal or promotional spikes.
The durability case is strong because prescriptions are the last thing households cut in a downturn, and an established local pharmacy carries switching friction tied to patient relationships, insurance setup, and refill history. Independent pharmacies also benefit from local loyalty and personal service that national chains struggle to replicate. The fully staffed team means the moat does not walk out the door with the seller.
Market tailwinds favor this asset: an aging population drives rising prescription volume per capita, and independent pharmacies in underserved or rural South Carolina markets can capture share where chains have pulled back. Specialty, compounding, and med-sync programs offer avenues to grow script count. Demographic demand here is structural, not cyclical.
The operator advantage is unusually clean: the listing states the business is easily run by an absentee owner, so a buyer does not need to be a licensed pharmacist or work the counter. That opens the deal to financial buyers and roll-up operators who can layer on management discipline. A multi-unit buyer could plug this into a shared purchasing and admin backbone immediately.

How to improve it

Audit the payer and PBM contract mix in the first 90 days to identify underperforming reimbursement lines and renegotiate or shift volume toward better-margin plans. With a 4.3% EBITDA margin, even a modest improvement in gross spread per script flows directly to the bottom line. This is the single highest-leverage lever in pharmacy.
Launch or expand a medication synchronization and auto-refill program to lift adherence and lock in recurring refill revenue. Synced refills increase script count per patient and smooth labor demand across the month. This directly deepens the recurring revenue base you are already paying for.
Add high-margin service lines such as compounding, immunizations, and point-of-care testing to diversify away from pure dispensing economics. These services carry far better margins than standard fills and strengthen the patient relationship. They also create revenue that is less exposed to PBM reimbursement pressure.
Review front-end retail and OTC merchandising, since many independents leave margin on the table with poorly managed non-prescription aisles. Optimizing product mix and private-label penetration can add incremental cash flow with minimal capital. Front-end sales also improve basket size per visit.
Negotiate wholesale drug purchasing through a buying group or GPO if not already maximized, since drug cost is the largest expense line. Even a 1 to 2 point improvement in COGS on $18M of throughput is material to EBITDA. Benchmark the current primary wholesaler agreement against alternatives.
Implement delivery and adherence packaging to capture homebound and senior patients, a growing demographic in central South Carolina. Convenience services build loyalty and defend against chain and mail-order competition. This can meaningfully grow script volume without opening a new location.

Diligence notes

Scrutinize the reimbursement and DIR fee trend over the last three years, because pharmacy EBITDA can erode from clawbacks and PBM fee structures even when revenue holds steady. Request detailed payer mix, gross profit per script, and a reconciliation of reported EBITDA to tax returns. This is the make-or-break item for the deal.
Verify the absentee-owned claim by mapping exactly who holds the pharmacist-in-charge license and reviewing staff tenure, compensation, and retention risk. If the lead pharmacist is the real operator and is not committed post-sale, the stated absentee economics collapse. Confirm employment agreements and any non-competes transfer.
Confirm whether the real estate is leased or owned and review lease terms, since the ask excludes real estate and an unfavorable or short lease could threaten continuity. Pharmacy location and visibility drive walk-in volume. Understand renewal options and rent escalators.
Analyze customer and prescriber concentration, including any dependence on a single nursing home, clinic, or physician group that could represent a large share of script volume. Loss of one institutional account could materially dent the $18.1M top line. Also check reliance on any single high-volume drug category.
Validate inventory valuation and whether drug inventory is included in the ask, because pharmacy inventory can be a six-figure working capital item that swings the effective purchase price. Confirm expiration exposure and controlled-substance compliance records. Review DEA and state board inspection history for any open issues.

Source

Originally listed on DealStream. View original listing →